CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 16 enrolled
Drug / intervention
Glutendietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03409796
NCT03409796N/ACompleted

Assessment of Immune Activation and Tolerance in Celiac Disease During Gluten Challenge

Takeda·interventional·Posted Jan 24, 2018·Updated May 24, 2022

In Brief

A clinical study evaluating Gluten for Celiac Disease. Completed, enrolled 16 participants across 2 sites.

Detailed Summary

The primary purpose of this study is to characterize changes in gluten-specific T cells and pathology in the small intestine with specific focus on biomarkers likely to change with therapeutic celiac disease (CeD) treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCeliac Disease
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedJan 24, 2018
Enrollment StartApr 24, 2018
Primary CompletionMay 2, 2019
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 8.4 years ago

Interventions

Glutendietary

Gluten powder.